Lisa M Nilsson
Overview
Explore the profile of Lisa M Nilsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Erlandsson M, Malmhall-Bah E, Chandrasekaran V, Andersson K, Nilsson L, Toyra Silfversward S, et al.
Cells
. 2025 Jan;
13(24.
PMID: 39768214
Hyperinsulinemia connects obesity, and a poor lipid profile, with type 2 diabetes (T2D). Here, we investigated consequences of insulin exposure for T cell function in the canonical autoimmunity of rheumatoid...
2.
Karlsson J, Sah V, Olofsson Bagge R, Kuznetsova I, Iqba M, Alsen S, et al.
Elife
. 2024 Sep;
12.
PMID: 39312285
Uveal melanoma (UM) is a rare melanoma originating in the eye's uvea, with 50% of patients experiencing metastasis predominantly in the liver. In contrast to cutaneous melanoma, there is only...
3.
Li Z, He B, Domenichini A, Satiaputra J, Wood K, Lakhiani D, et al.
J Clin Invest
. 2024 Sep;
134(18).
PMID: 39286984
T cell-based immunotherapies are a promising therapeutic approach for multiple malignancies, but their efficacy is limited by tumor hypoxia arising from dysfunctional blood vessels. Here, we report that cell-intrinsic properties...
4.
Nilsson L, Vilhav C, Karlsson J, Bourghardt Fagman J, Giglio D, Engstrom C, et al.
Gastro Hep Adv
. 2024 Aug;
1(6):1037-1048.
PMID: 39131259
Background And Aims: Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. Checkpoint immunotherapy has not yet shown encouraging results in pancreatic cancer possibly because of a poor...
5.
Sah V, Jespersen H, Karlsson J, Nilsson L, Bergqvist M, Johansson I, et al.
Cancer Res Commun
. 2023 Jun;
3(5):884-895.
PMID: 37377898
Purpose: Patients with metastatic uveal melanoma have limited therapeutic options and high mortality rate so new treatment options are needed. Patients And Methods: We previously reported that patients treated with...
6.
Forsberg E, Riise R, Saellstrom S, Karlsson J, Alsen S, Bucher V, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765608
Patients with metastatic melanoma have a historically poor prognosis, but recent advances in treatment options, including targeted therapy and immunotherapy, have drastically improved the outcomes for some of these patients....
7.
Liang F, Nilsson L, Byvald F, Rezapour A, Taflin H, Nilsson J, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740548
The diversity of T cells in the human liver may reflect the composition of TILs in CRLM. Our ex vivo characterization of CRLM vs. adjacent liver tissue detected CD103+CD39+CD8+ T...
8.
Sah V, Karlsson J, Jespersen H, Lindberg M, Nilsson L, Ny L, et al.
Melanoma Res
. 2021 Nov;
32(4):241-248.
PMID: 34753889
Targeted therapy and immunotherapy have revolutionized the treatment of metastatic skin melanoma but around half of all patients develop resistance early or late during treatment. The situation is even worse...
9.
Hofving T, Liang F, Karlsson J, Yrlid U, Nilsson J, Nilsson O, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503115
Traditionally, immune evasion and immunotherapy have been studied in cancers with a high mutational load such as melanoma or lung cancer. In contrast, small intestinal neuroendocrine tumours (SINETs) present a...
10.
Ny L, Jespersen H, Karlsson J, Alsen S, Filges S, All-Eriksson C, et al.
Nat Commun
. 2021 Aug;
12(1):5155.
PMID: 34453044
Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the...